 Shares of Citius Pharmaceuticals Inc. CTXR, -1.60 were up 18.5 in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lymphoma, which is a type of non-Hodgkin lymphoma. Citius said it plans to submit an application for approval of the investigational therapy, IOntak, to the Food and Drug Administration in the second half of this year based on this data. 